Genelux Corporation (NASDAQ:GNLX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Genelux Corporation (NASDAQ:GNLX) has earned an average rating of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $18.00.

Several analysts recently commented on the stock. Lucid Cap Mkts upgraded shares of Genelux to a “strong-buy” rating in a research report on Wednesday. Wall Street Zen raised Genelux from a “strong sell” rating to a “sell” rating in a report on Sunday, August 23rd. Benchmark reaffirmed a “speculative buy” rating on shares of Genelux in a research note on Tuesday, August 18th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a research note on Friday, July 17th.

Insider Buying and Selling at Genelux

In related news, Director John W. Smither sold 12,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $2.91, for a total transaction of $34,920.00. Following the sale, the director owned 91,403 shares of the company’s stock, valued at approximately $265,982.73. The trade was a 11.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Yong Yu sold 9,683 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $2.75, for a total value of $26,628.25. Following the sale, the insider directly owned 258,688 shares in the company, valued at $711,392. This trade represents a 3.61% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 59,822 shares of company stock valued at $164,402. 7.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new stake in shares of Genelux in the 2nd quarter worth about $35,000. Jefferies Financial Group Inc. purchased a new stake in shares of Genelux in the fourth quarter valued at about $48,000. Strive Financial Group LLC grew its position in shares of Genelux by 728.7% in the second quarter. Strive Financial Group LLC now owns 41,437 shares of the company’s stock valued at $125,000 after purchasing an additional 36,437 shares during the last quarter. Waystone Advisors LLC purchased a new position in shares of Genelux during the 4th quarter worth approximately $145,000. Finally, SteelPeak Wealth LLC raised its position in shares of Genelux by 458.9% during the 1st quarter. SteelPeak Wealth LLC now owns 60,895 shares of the company’s stock worth $147,000 after purchasing an additional 50,000 shares during the last quarter. Institutional investors and hedge funds own 37.33% of the company’s stock.

Genelux Stock Performance

Genelux stock opened at $2.53 on Friday. The company has a market capitalization of $114.46 million, a P/E ratio of -2.94 and a beta of 0.57. Genelux has a fifty-two week low of $2.29 and a fifty-two week high of $8.53. The stock has a 50-day simple moving average of $2.71 and a 200-day simple moving average of $2.76.

Genelux (NASDAQ:GNLX) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). As a group, analysts forecast that Genelux will post -0.81 earnings per share for the current year.

About Genelux

Genelux Corporation is a clinical-stage biotechnology company focused on developing and commercializing therapies for cancer. The company’s research centers on oncolytic immunotherapies, which are designed to selectively infect and destroy tumor cells while stimulating the body’s immune response against cancer.

Genelux’s lead investigational product is olvimulogene nanivacirepvec, also known as Olvi-Vec or GL-ONC1. Olvi-Vec is a modified vaccinia virus being evaluated in clinical studies for several solid tumors, including ovarian cancer and other advanced or recurrent cancers.